Top Medical News

Ocrelizumab Treatment Results in High NEDA Rates, Improvements in MS Symptoms

September 19, 2020

By Matt Hoffman

A pair of datasets from the phase 3b CASTING study of ocrelizumab (Ocrevus; Genentech) suggest that patients treated with the agent experienced high rates of no evidence of disease activity status regardless of prior DMT exposure.

Opicapone Treats Motor Fluctuations, Directional DBS Favored in PD, MRgFUS is Effective as Hand Tremor Treatment

September 19, 2020

By NeurologyLive Staff

Neurology News Network for the week ending September 19, 2020.

NeurologyLive Friday 5 — September 18, 2020

September 18, 2020

By NeurologyLive Staff

Take 5 minutes to catch up on NeurologyLive's highlights from the week ending September 18, 2020.

The Metamorphosis of Migraine: Evidence and Epidemiology

September 18, 2020

By Matt Hoffman

The ongoing fight to add to the epidemiologic understanding of migraine is explored in part 2 of this special 3-part multimedia series on the evolution of migraine care.

Ozanimod Shows Long-Term Safety, Efficacy in Open-Label Extension

September 18, 2020

By Marco Meglio

Along with being generally well tolerated, ozanimod was able to help most patients become relapse free without disability progression.

Featured


Latest Videos


Most Recent

Sumifilam Improves Multiple Alzheimer Disease Biomarkers in Phase 2b Study

September 17, 2020

The results point to the potential for sumifilam to become a transformative treatment for patients with Alzheimer disease.

Addressing Loneliness and Social Isolation in Patients With Parkinson Disease

September 17, 2020

The director of the VA Southwest Parkinson’s Disease Research, Education, and Clinical Centers offered background the inspiration for the study and why loneliness should be addressed in these patients.

Satralizumab Reduces Risk of Relapse, Including in Treatment-Naïve NMOSD

September 17, 2020

Two posters presented at MS 2020 confirm satralizumab’s ability to reduce protocol-defined relapse including in patients with treatment-naïve NMOSD.

Apomorphine Sublingual Film Shows Long-Term Efficacy in OFF Episode Treatment

September 16, 2020

The recently approved apomorphine sublingual film (Kynmobi; Sunovion) maintained efficacy over the long-term, with at least 74% of patients experiencing full ON within 30 minutes post-dose at each time point.

THN102 Is Safe, Improves Excessive Daytime Sleepiness in Parkinson Disease

September 16, 2020

The investigational drug consistently increased the proportion of patients no longer suffering from daytime sleepiness during treatment.

Jakob Dupont, MD: Phase 1 Data on Cell Therapy for Progressive MS

September 16, 2020

The executive vice president and head of global research and development at Atara Biotherapeutics spoke to the findings of a phase 1 study of the cell therapy ATA188.

Neurology Residency Training During a Pandemic

September 16, 2020

In part 2 of this interview, Leah Croll, MD, a neurology resident on the front lines of the COVID-19 pandemic, describes how her resident program experience was impacted by the pandemic.

Amantadine Shows Treatment Durability for Reducing OFF Time in Parkinson Disease

September 15, 2020

The percentage of patients reporting no OFF time and no impact of OFF on daily function more than doubled by the first on-treatment visit in this open-label trial.

Tau Levels May Predict Early Disability, Worse Prognosis in MS

September 15, 2020

Data show that higher CSF tau levels at diagnosis correlated with worse disability independent of age, though no such associations were identified with amyloid-beta.

Levodopa-Carbidopa Intestinal Gel Superior to Immediate Release Capsules for ON Time Without Dyskinesia

September 15, 2020

Benefits of levodopa-carbidopa intestinal gel lasted throughout the day and showed greater benefits of continuous dopaminergic stimulation in disease control than immediate release oral capsules.